Genetron Holdings Limited (NASDAQ: GTH) Stock Competitors & Peer Comparison
See GTH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GTH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTH | $4.03 | +0.12% | 127.3M | -1.11 | -$3.62 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
GTH vs DHR-PB Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GTH's ROE is -1.01%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, GTH is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for GTH.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
GTH vs TMO Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas TMO's P/E ratio is 27.70. In terms of profitability, GTH's ROE is -1.01%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GTH is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for GTH.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
GTH vs DHR Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas DHR's P/E ratio is 26.23. In terms of profitability, GTH's ROE is -1.01%, compared to DHR's ROE of +0.08%. Regarding short-term risk, GTH is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for GTH.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
GTH vs NTRA Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas NTRA's P/E ratio is -265.74. In terms of profitability, GTH's ROE is -1.01%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, GTH is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for GTH.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
GTH vs IQV Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas IQV's P/E ratio is 22.22. In terms of profitability, GTH's ROE is -1.01%, compared to IQV's ROE of +0.22%. Regarding short-term risk, GTH is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for GTH.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
GTH vs A Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, A has a market cap of 42.4B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas A's P/E ratio is 25.85. In terms of profitability, GTH's ROE is -1.01%, compared to A's ROE of +0.20%. Regarding short-term risk, GTH is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for GTH.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
GTH vs IDXX Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas IDXX's P/E ratio is 35.92. In terms of profitability, GTH's ROE is -1.01%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, GTH is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for GTH.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
GTH vs ILMN Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ILMN's P/E ratio is 44.19. In terms of profitability, GTH's ROE is -1.01%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, GTH is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for GTH.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
GTH vs WAT Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas WAT's P/E ratio is 30.49. In terms of profitability, GTH's ROE is -1.01%, compared to WAT's ROE of +0.02%. Regarding short-term risk, GTH is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for GTH.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
GTH vs DGX Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, DGX has a market cap of 27.3B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while DGX trades at $246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas DGX's P/E ratio is 24.39. In terms of profitability, GTH's ROE is -1.01%, compared to DGX's ROE of +0.14%. Regarding short-term risk, GTH is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for GTH.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
GTH vs MTD Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas MTD's P/E ratio is 30.58. In terms of profitability, GTH's ROE is -1.01%, compared to MTD's ROE of -12.00%. Regarding short-term risk, GTH is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for GTH.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
GTH vs LH Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas LH's P/E ratio is 18.72. In terms of profitability, GTH's ROE is -1.01%, compared to LH's ROE of +0.12%. Regarding short-term risk, GTH is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for GTH.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
GTH vs GH Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas GH's P/E ratio is -50.33. In terms of profitability, GTH's ROE is -1.01%, compared to GH's ROE of +2.11%. Regarding short-term risk, GTH is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for GTH.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
GTH vs EXAS Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GTH's ROE is -1.01%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, GTH is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for GTH.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
GTH vs MEDP Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas MEDP's P/E ratio is 36.37. In terms of profitability, GTH's ROE is -1.01%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, GTH is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for GTH.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
GTH vs ILMNV Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to ILMNV's ROE of N/A. Regarding short-term risk, GTH is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for GTH.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
GTH vs RVTY Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas RVTY's P/E ratio is 26.19. In terms of profitability, GTH's ROE is -1.01%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, GTH is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for GTH.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
GTH vs PKI Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas PKI's P/E ratio is 41.45. In terms of profitability, GTH's ROE is -1.01%, compared to PKI's ROE of +0.03%. Regarding short-term risk, GTH is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for GTH.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
GTH vs ICLR Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ICLR's P/E ratio is 14.07. In terms of profitability, GTH's ROE is -1.01%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, GTH is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for GTH.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
GTH vs CRL Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CRL's P/E ratio is 27.53. In terms of profitability, GTH's ROE is -1.01%, compared to CRL's ROE of -0.08%. Regarding short-term risk, GTH is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for GTH.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
GTH vs QGEN Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas QGEN's P/E ratio is 17.55. In terms of profitability, GTH's ROE is -1.01%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, GTH is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for GTH.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
GTH vs RDNT Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas RDNT's P/E ratio is 167.65. In terms of profitability, GTH's ROE is -1.01%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, GTH is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for GTH.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
GTH vs SHC Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas SHC's P/E ratio is 19.77. In terms of profitability, GTH's ROE is -1.01%, compared to SHC's ROE of +0.27%. Regarding short-term risk, GTH is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for GTH.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
GTH vs BLLN Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BLLN trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BLLN's P/E ratio is 148.96. In terms of profitability, GTH's ROE is -1.01%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, GTH is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
GTH vs SYNH Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GTH's ROE is -1.01%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GTH is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for GTH.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
GTH vs GRAL Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas GRAL's P/E ratio is -7.78. In terms of profitability, GTH's ROE is -1.01%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, GTH is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for GTH.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
GTH vs OLK Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas OLK's P/E ratio is -96.59. In terms of profitability, GTH's ROE is -1.01%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GTH is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for GTH.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
GTH vs VCYT Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas VCYT's P/E ratio is 20.07. In terms of profitability, GTH's ROE is -1.01%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, GTH is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for GTH.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
GTH vs WGS Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas WGS's P/E ratio is 262.89. In terms of profitability, GTH's ROE is -1.01%, compared to WGS's ROE of -0.39%. Regarding short-term risk, GTH is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for GTH.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
GTH vs CDNA Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CDNA's P/E ratio is 62.67. In terms of profitability, GTH's ROE is -1.01%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, GTH is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for GTH.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
GTH vs PSNL Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas PSNL's P/E ratio is -14.77. In terms of profitability, GTH's ROE is -1.01%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, GTH is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for GTH.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
GTH vs OPK Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas OPK's P/E ratio is -5.81. In terms of profitability, GTH's ROE is -1.01%, compared to OPK's ROE of -0.06%. Regarding short-term risk, GTH is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for GTH.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
GTH vs CSTL Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CSTL's P/E ratio is -53.79. In terms of profitability, GTH's ROE is -1.01%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, GTH is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for GTH.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
GTH vs FLGT Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, GTH's ROE is -1.01%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, GTH is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for GTH.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
GTH vs GRALV Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas GRALV's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to GRALV's ROE of N/A. Regarding short-term risk, GTH is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for GTH.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
GTH vs NEO Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas NEO's P/E ratio is 145.31. In terms of profitability, GTH's ROE is -1.01%, compared to NEO's ROE of -0.06%. Regarding short-term risk, GTH is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for GTH.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
GTH vs CO Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CO's P/E ratio is 5.06. In terms of profitability, GTH's ROE is -1.01%, compared to CO's ROE of +0.11%. Regarding short-term risk, GTH is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for GTH.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
GTH vs MYGN Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas MYGN's P/E ratio is -29.85. In terms of profitability, GTH's ROE is -1.01%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, GTH is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for GTH.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
GTH vs FLDM Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GTH's ROE is -1.01%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, GTH is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for GTH.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
GTH vs PRENW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas PRENW's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, GTH is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
GTH vs BDSX Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BDSX has a market cap of 225.5M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BDSX trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BDSX's P/E ratio is -8.74. In terms of profitability, GTH's ROE is -1.01%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, GTH is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
GTH vs XGN Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas XGN's P/E ratio is -9.25. In terms of profitability, GTH's ROE is -1.01%, compared to XGN's ROE of -1.22%. Regarding short-term risk, GTH is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for GTH.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
GTH vs IMDX Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas IMDX's P/E ratio is -2.70. In terms of profitability, GTH's ROE is -1.01%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, GTH is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for GTH.Check IMDX's competition here
Genetic Technologies Limited (NASDAQ: GENE)
GTH vs GENE Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas GENE's P/E ratio is -38.25. In terms of profitability, GTH's ROE is -1.01%, compared to GENE's ROE of -1.85%. Regarding short-term risk, GTH is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for GTH.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
GTH vs SERA Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, SERA has a market cap of 76M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas SERA's P/E ratio is -3.06. In terms of profitability, GTH's ROE is -1.01%, compared to SERA's ROE of -0.47%. Regarding short-term risk, GTH is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for GTH.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
GTH vs PRPO Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas PRPO's P/E ratio is -104.77. In terms of profitability, GTH's ROE is -1.01%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, GTH is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for GTH.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
GTH vs MDXH Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas MDXH's P/E ratio is -1.77. In terms of profitability, GTH's ROE is -1.01%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, GTH is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for GTH.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
GTH vs QUCY Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas QUCY's P/E ratio is -0.06. In terms of profitability, GTH's ROE is -1.01%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, GTH is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for GTH.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
GTH vs AKU Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas AKU's P/E ratio is -0.13. In terms of profitability, GTH's ROE is -1.01%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GTH is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for GTH.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
GTH vs CEMI Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GTH's ROE is -1.01%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GTH is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for GTH.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
GTH vs ENZ Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GTH's ROE is -1.01%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, GTH is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for GTH.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
GTH vs PMD Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas PMD's P/E ratio is -5.24. In terms of profitability, GTH's ROE is -1.01%, compared to PMD's ROE of -0.32%. Regarding short-term risk, GTH is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for GTH.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
GTH vs ME Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ME's P/E ratio is -0.03. In terms of profitability, GTH's ROE is -1.01%, compared to ME's ROE of -42.03%. Regarding short-term risk, GTH is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for GTH.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
GTH vs MYNZ Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, GTH's ROE is -1.01%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, GTH is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for GTH.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
GTH vs BNR Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BNR's P/E ratio is -13.29. In terms of profitability, GTH's ROE is -1.01%, compared to BNR's ROE of -0.13%. Regarding short-term risk, GTH is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
GTH vs ADVB Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ADVB's P/E ratio is -73.45. In terms of profitability, GTH's ROE is -1.01%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, GTH is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for GTH.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
GTH vs CHEK Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GTH's ROE is -1.01%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GTH is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for GTH.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
GTH vs CNTG Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GTH's ROE is -1.01%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GTH is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for GTH.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
GTH vs NDRA Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas NDRA's P/E ratio is -0.73. In terms of profitability, GTH's ROE is -1.01%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, GTH is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for GTH.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
GTH vs APDN Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas APDN's P/E ratio is -0.10. In terms of profitability, GTH's ROE is -1.01%, compared to APDN's ROE of -7.23%. Regarding short-term risk, GTH is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for GTH.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
GTH vs NVTA Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GTH's ROE is -1.01%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GTH is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for GTH.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
GTH vs LMDXW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GTH's ROE is -1.01%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GTH is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
GTH vs LMDX Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GTH's ROE is -1.01%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GTH is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for GTH.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
GTH vs BIAFW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, GTH's ROE is -1.01%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, GTH is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
GTH vs DMTK Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GTH's ROE is -1.01%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GTH is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for GTH.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
GTH vs NOTV Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GTH's ROE is -1.01%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GTH is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for GTH.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
GTH vs BIAF Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BIAF's P/E ratio is -0.73. In terms of profitability, GTH's ROE is -1.01%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, GTH is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
GTH vs SQL Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas SQL's P/E ratio is -0.40. In terms of profitability, GTH's ROE is -1.01%, compared to SQL's ROE of -30.46%. Regarding short-term risk, GTH is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for GTH.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
GTH vs AWH Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas AWH's P/E ratio is -0.09. In terms of profitability, GTH's ROE is -1.01%, compared to AWH's ROE of +1.62%. Regarding short-term risk, GTH is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for GTH.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
GTH vs HTGM Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GTH's ROE is -1.01%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GTH is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for GTH.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
GTH vs BIOC Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GTH's ROE is -1.01%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GTH is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
GTH vs ISPC Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas ISPC's P/E ratio is -0.04. In terms of profitability, GTH's ROE is -1.01%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, GTH is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for GTH.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
GTH vs SQLLW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, GTH's ROE is -1.01%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, GTH is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
GTH vs WGSWW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, GTH's ROE is -1.01%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, GTH is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for GTH.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
GTH vs MEUSW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, GTH is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
GTH vs NDRAW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, GTH is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
GTH vs DHR-PA Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GTH's ROE is -1.01%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, GTH is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for GTH.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
GTH vs PRXL Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas PRXL's P/E ratio is 42.97. In terms of profitability, GTH's ROE is -1.01%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GTH is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for GTH.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
GTH vs OCDX Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GTH's ROE is -1.01%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GTH is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for GTH.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
GTH vs BNGOW Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, GTH is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for GTH.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
GTH vs CHEKZ Comparison September 2026
Genetron Holdings Limited (NASDAQ: GTH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTH stands at 127.3M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GTH is priced at $4.03 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTH currently has a P/E ratio of -1.11, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GTH's ROE is -1.01%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GTH is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for GTH.Check CHEKZ's competition here